Synapse Reaches Self Reported Market Capitalization of 96.25 Million

TOVX Stock  USD 1.28  0.02  1.59%   
Slightly above 51% of Theriva Biologics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Theriva Biologics suggests that some traders are interested. Theriva Biologics' investing sentiment can be driven by a variety of factors including economic data, Theriva Biologics' earnings reports, geopolitical events, and overall market trends.
  
Synapse traded up 7.1 percent against the U.S. dollar during the 24 hour period ending at 000 AM E.T. on October 13th. Over the last week, Synapse has traded up 11.3 percent against the U.S. dollar. One Synapse token can now be purchased for about 0.53 or 0.00000833 BTC on popular cryptocurrency exchanges. Synapse has a

Read at thelincolnianonline.com
news
  

Theriva Biologics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Theriva Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Theriva Biologics Fundamental Analysis

We analyze Theriva Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theriva Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theriva Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Earnings Per Share

Earnings Per Share Comparative Analysis

Theriva Biologics is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

Theriva Biologics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Theriva Biologics stock to make a market-neutral strategy. Peer analysis of Theriva Biologics could also be used in its relative valuation, which is a method of valuing Theriva Biologics by comparing valuation metrics with similar companies.

Peers

Theriva Biologics Related Equities

XCURExicure   69.24   
0%
100.0%
GOVXGeoVax Labs   9.26   
0%
13.0%
PTIXProtagenic Therapeutics   6.56   
0%
9.0%
MRKRMarker Therapeutics   5.08   
0%
7.0%
AVTXAvalo Therapeutics   4.97   
0%
7.0%
BDRXBiodexa Pharmaceticals   3.86   
0%
5.0%
PMVPPmv Pharmaceuticals   2.55   
0%
3.0%
PRAXPraxis Precision   1.97   
0%
2.0%
SABSSAB Biotherapeutics   1.95   
0%
2.0%
LSTALisata Therapeutics   1.41   
0%
2.0%
REVBRevelation Biosciences   1.33   
0%
1.0%
VCNXVaccinex   0.56   
0%
1.0%
LUMOLumos Pharma   0.46   
1.0%
0%
VRPXVirpax Pharmaceuticals   3.39   
4.0%
0%
SLRXSalarius Pharmaceuticals   6.16   
8.0%
0%

Additional Tools for Theriva Stock Analysis

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.